President Trump published letters to 17 major pharma companies reiterating his requirements for them to fulfill his MFN order ...

Approval is based on results from the Phase III VALIANT trial (NCT05067127), in which Empaveli demonstrated a 68% reduction ...

Aetna enhances user experience with AI-driven Care Paths, simplifying health navigation and personalizing care for members ...

The results showed that people started mirroring the eating habits of GLP-1 users even when they weren’t taking the ...